Table 1.
Patient characteristics and results of HLA ligandomics performed by tandem mass spectrometry.
| UPN | Diagnosis | HLA-A* | HLA-B* | Tissue | Sample weight | HLA class I | HLA class II | RIN | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [mg] | Peptides (n=) | Binders (n=) | Binders [%] | Peptides (n=) | ||||||||
| IRISS01 | mCRC | 24 | 66 | 27 | 44 | Tumor | 160 | 1,785 | 1,508 | 84.5 | 850 | 7.2 |
| NMT | 710 | 1,917 | 1,507 | 78.6 | 1490 | 7.1 | ||||||
| IRISS05 | mCRC | 01 | 02 | 08 | 18 | Tumor | 46 | 260 | 198 | 76.2 | 556 | 8.4 |
| NMT | 290 | 922 | 820 | 88.9 | 803 | 7.1 | ||||||
| IRISS06 | mCRC | 02 | 24 | 15 | 35 | Tumor | 54 | 711 | 666 | 93.7 | n.d. | 7.4 |
| NMT | n.d. | n.d. | n.d. | n.d. | n.d. | 3.3 | ||||||
| IRISS08 | mCRC | 02 | 33 | 14 | 18 | Tumor | 24 | 231 | 175 | 75.8 | 220 | 8.6 |
| NMT | 280 | 1101 | 923 | 83.8 | 631 | 7.5 | ||||||
| IRISS09 | mCRC | 01 | 08 | Tumor | n.d. | n.d. | n.d. | n.d. | n.d. | n.d. | ||
| NMT | 130 | 560 | 341 | 60.9 | 445 | 8.3 | ||||||
| IRISS12 | mCRC | 01 | 02 | 08 | 27 | Tumor | 920 | 1887 | 1714 | 90.8 | 1461 | 6.9 |
| NMT | 840 | 1372 | 1244 | 90.7 | 1307 | 8.3 | ||||||
CRC, colorectal cancer; HLA, human leukocyte antigen; m, metastasized; n.d., not determined; NMT, non-malignant tissue; RIN, RNA integrity number; RNA, ribonucleic acid; UPN, uniform patient number. Binders were defined as HLA-eluted peptides predicted to bind to the respective HLA alleles of the patient above the thresholds given in Materials and Methods determined by suitable software.